Page last updated: 2024-08-17

prednisone and thalidomide

prednisone has been researched along with thalidomide in 294 studies

Research

Studies (294)

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (2.38)	18.7374
1990's	13 (4.42)	18.2507
2000's	77 (26.19)	29.6817
2010's	181 (61.56)	24.3611
2020's	16 (5.44)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Trautman, JR	1
Boisnic, S; Tovaru, S	1
Friedman, KJ; Hess, AD; Santos, GW; Vogelsang, GB	1
Bullock, WE	1
Harnisch, JP; Miller, RA; Rea, TH; Shen, JY	1
Boone, RM; Kluin-Nelemans, HC; Ranselaar, CG	1
Gordon, H	1
Rea, TH; Yoshida, T	1
Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K	1
Kania, RJ; McGarr, J; Molloy, PJ; Naum, SM; Van Thiel, DH	1
Baumgartner, WA; Cho, PW; Gaudin, PB; Hruban, RH; Kumar, P; Stuart, RS; Uthoff, K; Vogelsang, G; Zehr, KJ	1
Bowers, KE; Gaspari, AA; Holm, AL; McMeekin, TO	1
Bretzel, G; Sticht-Groh, V	1
Bellomo, A; Schorr-Lesnick, B	1
Naafs, B	1
Chang, B; Gu, H; Li, G; Qian, H	1
Abalos, RM; Balagon, MV; Cellona, RV; Fajardo, TJ; Kaplan, G; Moreira, AL; Tan, EV; Villahermosa, LG; Walsh, GP	1
Fikrig, SM; Jibaly, RM; Moallem, H; Rabinowitz, SS	1
Koblenzer, PS; Lee, JB	1
Ahern, KP; Cabrera, A; Levis, WR; Vides, EA	1
Anasetti, C; Appelbaum, FR; Deeg, HJ; Flowers, ME; Koc, S; Leisenring, W; Martin, PJ; Nash, RA; Sanders, JE; Storb, R; Witherspoon, RP	1
Arora, M; Blazar, BR; Davies, SM; Defor, T; Enright, H; Miller, WJ; Wagner, JE; Weisdorf, DF	1
Desikan, RK; Jagannath, S	1
Ahmad, I; Alam, AR; Becker, JL; Chanan-Khan, A; Hahn, T; Islam, T; McCarthy, PL; Wentling, D	1
Huijgens, PC; Zweegman, S	1
Rea, TH	1
Drach, J; Kaufmann, H; Nösslinger, T; Raderer, M; Urbauer, E	1
Geraldo, NT; Moraes, MO; Salles, AM; Sampaio, EP; Sarno, EN; Teles, RM	1
Elliott, M; Gray, LA; Kaufmann, SH; Li, CY; Mesa, RA; Pardanani, A; Reeder, T; Schroeder, G; Steensma, DP; Tefferi, A; Wiseman, G; Zeldis, JB	1
Charte González, A; Folch Civit, J; Robert Olalla, J; Rufi Rigau, G; Sanuy Jiménez, B; Vidaller Palacín, A	1
Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL	1
Messori, A; Santarlasci, B; Trippoli, S	1
Jäger, U	1
Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M	1
Ackermann, J; Dimou, G; Drach, J; Gisslinger, H; Kees, M; Lechner, K; Sillaber, C	1
Deng, YJ; Hao, F; Liu, RQ; Sun, RS; Wang, JW; Xiang, MM; Ye, QY; Zhong, BY; Zhou, CL	1
Sarmadi, M; Ship, JA	1
Chehal, A; Elhajj, I; Mourad, YA; Shamseddine, A; Taher, A	1
Achirafi, A; de Carsalade, GY; Flageul, B	1
Elliott, MA; Mesa, RA; Schroeder, G; Tefferi, A	1
Bystryn, JC; Cunha, PR; de Oliveira, JR; Jamora, J; Salles, MJ	1
Bertola, A; Boccadoro, M; Bringhen, S; Cavallo, F; Falco, P; Palumbo, A	1
Belch, AR; Chen, CI; Ding, K; Howson-Jan, K; Kovacs, MJ; Meyer, RM; Roy, J; Sadura, A; Shepherd, L; Shustik, C; Stewart, AK; White, D	1
Cervantes, F	1
Anderson, KC; Palumbo, A	1
de Moraes-Vasconcelos, D; Machado, MC; Nishimura, MY; Rivitti, EA; Varella, TC	1
Bertola, A; Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Falco, P; Grasso, M; Musto, P; Nunzi, M; Palumbo, A	1
Enschede, SH; Gregory, SA; Larson, ML	1
Silver, R	1
Kyle, RA; Rajkumar, SV	1
McClain, KL	1
Barbui, AM; Barbui, T; Belfiglio, M; Crippa, C; Delaini, F; Galli, M; Giussani, U; Nicolucci, A; Rambaldi, A; Valentini, M	1
Kunihiko, M; Mariko, Y; Shinichiro, O; Yasuo, I; Yusuke, T; Yutaka, H	1
Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Capparella, V; Caravita, T; Catalano, L; Ceccarelli, M; Ciccone, G; De Stefano, V; Falco, P; Galli, M; Grasso, M; Liberati, AM; Merla, E; Musto, P; Palumbo, A; Petrucci, MT; Rossini, F; Zamagni, E	1
Kyle, RA; Vincent Rajkumar, S	1
Burton, A	1
Horii, A; Kubo, T; Mitani, K; Mizuki, M; Murata, J; Tamura, M	1
Boccadoro, M; Palumbo, A; Rodeghiero, F; Rus, C; Zeldis, JB	1
Byars, T; Cox, CE; Hartung, C; Judson, MA; Silvestri, J	1
Facon, T	2
Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P	1
Merlini, G; Palladini, G; Perfetti, V	1
Dürk, HA	1
Abonour, R; Ansari, RH; Cripe, LD; Fausel, C; Fisher, WB; Juliar, BE; Smith, GG; Suvannasankha, A; Wood, LL; Yiannoutsos, CT	1
Berrebi, A; Feldberg, E; Shvidel, L; Spivak, I	1
Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I	1
Ludwig, H; Schreder, M; Strasser-Weippl, K; Zojer, N	1
Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y	1
Fassas, AB; Tricot, G	1
Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB	1
Boccadoro, M; Palumbo, A	1
Anglaret, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Casassus, P; Chaleteix, C; Dib, M; Dorvaux, V; Doyen, C; Facon, T; Grosbois, B; Guillerm, G; Harousseau, JL; Hulin, C; Jardel, H; Jaubert, J; Kolb, B; Maisonneuve, H; Martin, C; Mary, JY; Mathiot, C; Monconduit, M; Pegourie, B; Renaud, M; Troncy, J; Voillat, L; Yakoub-Agha, I	1
Ganser, A; Peest, D	1
Faiman, B	1
Darre, S; Facon, T	1
Alvarenga, FF; Esquenazi, D; Miranda, A; Moreira, AL; Nery, JA; Pereira, GM; Sarno, EN	1
Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV	1
Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Capaldi, A; Caravita, T; Cavallo, F; Cavo, M; Ciccone, G; Derudas, D; Dore, F; Falco, P; Falcone, A; Gay, F; Liberati, AM; Montanaro, M; Musto, P; Palumbo, A; Ria, R; Zambello, R	1
Facon, T; Hulin, C; Moreau, P	2
Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A	1
Bladé, J; Rosiñol, L	1
Ambrus, JL; Islam, A	1
Avvisati, G	1
Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC	1
Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A	1
Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M	1
Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB	1
Azaïs, I; Benboubker, L; Casassus, P; Decaux, O; Dib, M; Doyen, C; Eschard, JP; Facon, T; Fontan, J; Garderet, L; Guillerm, G; Hulin, C; Lafon, I; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Rodon, P; Salles, B; Virion, JM	1
Barlogie, B; Bolejack, V; Crowley, JJ; Durie, BG; Hussein, MA; Jakubowiak, AJ; Zonder, JA	1
Deschler, B; Engelhardt, M; Ihorst, G; Jakob, C; Kleber, M; Koch, B; Liebisch, P; Sezer, O	1
Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y	1
Boone, SL; Fabi, SG; Hill, C; West, DP; Witherspoon, JN	1
Bueso-Ramos, C; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Verstovsek, S	1
García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L	1
Azaïs, I; Brault, R; Debiais, F	1
Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F	1
Anderson, K; Benevolo, G; Boccadoro, M; Bringhen, S; Cavallo, F; Gaidano, G; Gay, F; Genuardi, M; Iacobelli, M; Kotwica, K; Larocca, A; Magarotto, V; Masini, L; Mitsiades, C; Palumbo, A; Richardson, P; Rossi, D; Rus, C	1
Bladé, J; Davies, F; Delforge, M; Facon, T; Garcia Sanz, R; Kropff, M; Leal da Costa, F; Moreau, P; Morgan, G; Palumbo, A; Schey, S	1
Cheung, K; Coleman, M; Elstrom, R; Faye, A; Furman, RR; Hajjar, KA; Lachs, M; Leonard, JP; Martin, P; Ruan, J	1
Arlen, PM; Chen, CC; Dahut, WL; Figg, WD; Gulley, JL; Jones, E; Kim, YS; Latham, L; Lee, MJ; Madan, RA; Ning, YM; Parnes, HL; Steinberg, SM; Sun, H; Trepel, JB; Woo, S; Wright, JJ	1
Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G	1
Bagratuni, T; Boyd, K; Davenport, EL; Davies, FE; Dickens, NJ; Gonzalez de Castro, D; Gregory, W; Johnson, DC; Morgan, GJ; Walker, BA; Wu, P	1
Abildgaard, N; Ahlberg, L; Björkstrand, B; Carlson, K; Dahl, IM; Fayers, P; Forsberg, K; Gimsing, P; Gulbrandsen, N; Haukås, E; Hjertner, O; Hjorth, M; Juliusson, G; Karlsson, T; Knudsen, LM; Linder, O; Mellqvist, UH; Nesthus, I; Nielsen, JL; Rolke, J; Strandberg, M; Sørbø, JH; Turesson, I; Waage, A; Wisløff, F	1
Boccadoro, M; Dispenzieri, A; Falco, P; Gay, F; Gertz, MA; Keith Stewart, A; Kumar, S; Palumbo, A; Petrucci, MT; Vincent Rajkumar, S	1
Alesiani, F; Blasi, N; Boccadoro, M; Bringhen, S; Brunori, M; Catarini, M; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Larocca, A; Leoni, P; Mele, A; Offidani, M; Oliva, S; Palumbo, A; Polloni, C; Visani, G	1
Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S	1
Lonial, S	2
Datta, YH; Ninan, MJ	1
Cripe, LD; Li, CY; Litzow, M; Mesa, RA; Paietta, E; Rowe, JM; Tallman, MS; Tefferi, A; Yao, X	1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB	1
Rajkumar, SV	2
de Witte, T; Holle, N; Mandigers, C; Raymakers, R; Schaap, N	1
Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D	1
Han, XH; He, XH; Liu, P; Liu, XF; Qin, Y; Shi, YK; Yang, JL; Yang, S; Yao, JR; Zhang, CG; Zhou, LQ; Zhou, SY	1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D	1
Ali, R; Aydogdu, I; Beksac, M; Firatli-Tuglular, T; Goker, H; Gulbas, Z; Haznedar, R; Karakus, S; Kaya, E; Kaygusuz, I; Konuk, N; Ozdogu, H; Ozet, G; Sucak, G; Undar, L	1
Palumbo, A	1
Berthou, C; Eveillard, JR; Guillerm, G; Ianotto, JC; Tempescul, A	1
Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K	1
Camoriano, J; Geyer, S; Mesa, RA; Pardanani, A; Steensma, DP; Tefferi, A; Thapaliya, P; Wu, W	1
Harousseau, JL	2
Adams, D; Bourhis, JH; Lacroix, C; Lozeron, P; Ribrag, V; Theaudin, M	1
Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Roy, V	1
Mateos, MV; San-Miguel, J	1
Schots, R	1
Ammerlaan, AH; Lokhorst, HM; Schaafsma, MR; Sinnige, HA; Sonneveld, P; Termorshuizen, F; Uyl-de Groot, CA; van der Griend, R; van Marwijk Kooy, M; Verelst, SG; Wijermans, PW; Wittebol, S; Zweegman, S	1
Kyle, RA; Steensma, DP	1
Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M	1
Rexer, H	1
Balleari, E; Buda, G; Consoli, U; Di Renzo, N; Ferrara, R; Fragasso, A; Lazzaro, A; Marcheselli, R; Masini, L; Morabito, F; Musto, P; Neri, S; Pastorini, A; Polimeno, G; Quarta, G; Sacchi, S; Vigliotti, ML; Zoboli, A	1
Beksaç, M; Benboubker, L; Bringhen, S; Caravita, T; Facon, T; Fayers, PM; Gimsing, P; Haznedar, R; Hulin, C; Mary, JY; Moreau, P; Musto, P; Palumbo, A; Schaafsma, M; Sonneveld, P; Termorshuizen, F; Turesson, I; Waage, A; Wijermans, P	1
Bisi, MC; Dias, FS; do Prado, AD; Piovesan, DM; Schmoeller, D; Staub, HL	1
Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP	1
Ansell, SM; Habermann, TM; Inwards, DJ; Johnston, PB; Klebig, RR; LaPlant, B; Macon, WR; Micallef, IN; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Witzig, TE	1
Jin, X; Shi, R; Zhao, X; Zheng, J	1
Han, TX; Kuang, WY; Li, CF; Wang, J; Zhou, YF	1
Agullo, A; Andres, M; Batlle, E; Martinez, A; Negrete, R	1
Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I	1
Benchikhi, H; Bouayad, K; Chiheb, S; Hali, F; Khadir, K; Mikou, N	1
D'Arena, G; Di Renzo, N; Falcone, A; Ferrara, F; Guariglia, R; Mansueto, G; Martorelli, MC; Mastrullo, L; Musto, P; Onofrillo, D; Pagano, L; Palumbo, A; Pietrantuono, G; Semenzato, G; Specchia, G; Valentini, CG; Venditti, A; Villani, O	1
Fan, WF; Liu, FY; Meng, LJ; Pu, XL; Wang, J; Yang, M	1
Abkowitz, JL; Keel, SB; Kirn-Safran, CB; O'Leary, MN; Phelps, S; Sabo, KM	1
Min, CK	1
Bae, SH; Bang, SM; Chang, HJ; Do, YR; Lee, JH; Lee, JL; Nam, SH; Yoon, SS	1
Abumiya, M; Kameoka, Y; Miura, M; Sawada, K; Takahashi, N	1
Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL	1
Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S	1
Habermann, TM	1
Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M	1
Badros, AZ	1
Chocholska, S; Dmoszynska, A; Grzasko, N; Hajek, R; Hus, M; Jurczyszyn, A; Morawska, M; Pluta, A; Walter-Croneck, A	1
Charliński, G; Jedrzejczak, WW; Wiater, E	1
Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E	1
Bertolini, F	1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; García-Sanz, R; González, Y; Granell, M; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Oriol, A; Palomera, L; Peñalver, FJ; Pérez, M; Polo, M; Ribera, JM; San-Miguel, JF; Teruel, AI	1
Fabiano, AJ; Fenstermaker, RA; Qiu, J; Rigual, D	1
Jian, X; Liu, H; Zhang, W; Zhang, Z; Zhou, Q	1
Benevolo, G; Boccadoro, M; Bringhen, S; Carella, AM; Cavallo, F; De Paoli, L; Falco, P; Freilone, R; Gaidano, G; Gay, F; Grasso, M; Guglielmelli, T; Larocca, A; Mina, R; Molica, S; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Rocci, A; Rossi, D; Siez, ML	1
Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ	1
Bocchia, M; Cencini, E; Defina, M; Fabbri, A; Fontanelli, G; Gozzetti, A; Mazzei, MA; Pietrini, A; Volterrani, L	1
Beckers, MM; Huls, G	1
Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J	1
Bahlis, NJ; Belch, A; Brundage, M; Cantin, G; Chapman, JA; Harnett, EL; Kovacs, MJ; Lacy, MQ; Marcellus, DC; Meyer, RM; Reece, D; Reiman, T; Roy, J; Rubinger, M; Sabry, W; Shepherd, L; Shustik, C; Song, K; Stewart, AK; Sussman, J; Tompkins, KA; Trudel, S; White, D	1
Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST	1
Hu, YM; Li, KY; Lü, JB	1
Lonial, S; Miguel, JF	1
Mina, R; Palumbo, A	1
Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A	1
Goldschmidt, H; Nitschmann, S	1
Baldi, I; Bottelli, C; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; De Masi, P; Gaidano, G; Ladetto, M; Liberati, AM; Orsucci, L; Palumbo, A; Pavone, V; Perticone, S; Rossi, G; Rossini, B; Salvi, F; Tucci, A; Vitolo, U; Zanni, M	1
Chevret, S; Facon, T; Mary, JY; Moatti, M; Moreau, P; Zohar, S	1
Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M	1
Baldi, I; Boccadoro, M; Bringhen, S; Carella, AM; Corradini, P; Crippa, C; Galli, M; Giuliani, N; Guglielmelli, T; La Verde, G; Larocca, A; Magarotto, V; Marcatti, M; Mina, R; Montefusco, V; Omedé, P; Palumbo, A; Rossi, D; Rota-Scalabrini, D; Santagostino, A	1
Drach, J; Drach-Schauer, B; Eder, S; Lamm, W	1
Alici, E; Aschan, J; Gahrton, G; Holmberg, E; Liwing, J; Lund, J; Nahi, H; Uttervall, K	1
Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J	1
Amías-Lamana, V; Cabiró-Badimón, I; Hoyos-Chacón, J; Mesa-Gutiérrez, JC; Porta-Monnet, J; Rouras-López, A	1
Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S	1
Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R	1
Aslam, A; Chalmers, R	1
Agostinelli, C; Argnani, L; Broccoli, A; Celli, M; Pellegrini, C; Pileri, S; Zinzani, PL	1
Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S	1
Delforge, M; Devos, T; Dierickx, D; Janssens, A; Raddoux, J; Verhoef, G; Zelis, N	1
Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT	1
Baldi, I; Botto, B; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; Congiu, A; Dreyling, M; Fattori, PP; Franceschetti, S; Gaidano, G; Gaudiano, M; Inghirami, G; Ladetto, M; Liberati, AM; Molinari, AL; Pavone, V; Rossi, G; Salvi, F; Spina, M; Vitolo, U; Zaccaria, A; Zanni, M; Zinzani, P	1
Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G	1
Cortes, J; Daver, N; Jabbour, E; Kadia, T; Kantarjian, H; Newberry, K; Pemmaraju, N; Pierce, S; Shastri, A; Verstovsek, S; Zhou, L	1
Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A	1
Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI	1
Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J	1
Ansell, SM; Foran, JM; Gascoyne, RD; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; Macon, WR; Micallef, IN; Nelson, GD; Nowakowski, GS; Porrata, LF; Reeder, CB; Rivera, CE; Thompson, CA; Witzig, TE	1
Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S	1
Fang, L; Hu, N; Li, B; Pan, L; Qin, T; Qu, S; Xiao, Z; Xu, J; Xu, Z; Zhang, H; Zhang, Y	1
Ben Yehuda, D; Boccadoro, M; Cafro, A; Caravita, T; Carella, AM; Catalano, L; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Evangelista, A; Gay, F; Genuardi, M; Marcatti, M; Musto, P; Nagler, A; Offidani, M; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Ribakovsky, E; Zamagni, E	1
Anderson, K; Attal, M; Avet-Loiseau, H; Bahlis, N; Banos, A; Belch, AR; Benboubker, L; Binder, D; Catalano, J; Cavenagh, J; Cavo, M; Chen, C; Chen, G; de la Rubia, J; Delforge, M; Dimopoulos, MA; Dispenzieri, A; Ervin-Haynes, A; Facon, T; Fermand, JP; Geraldes, C; Hulin, C; Jacques, C; Knight, R; Lee, JJ; Ludwig, H; Moreau, P; Oriol, A; Pinto, A; Qiu, L; Tiab, M; Van Oostendorp, J; Weisel, K; White, DJ	1
Cao, C; Kai, S; Liu, T; Wang, L; Xiang, B; Zhu, H	1
Yamamoto, K	1
Tsurumi, H	1
Bahlis, N; Belch, A; Chapman, JA; Chen, C; Davies, GA; Kouroukis, CT; Kovacs, MJ; Meyer, RM; Reece, D; Roy, J; Shepherd, L; Stewart, KA; Voralia, M; Zhu, L	1
Escudero-Vilaplana, V; Osorio Prendes, S; Sanjurjo Sáez, M	1
Fowler, NH	1
Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE	1
Boccardo, F	1
Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Olza, MO; de Wit, R; Doner, K; Fandi, A; Fizazi, K; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, S; Petrylak, DP; Sternberg, CN; Van As, N; Vogelzang, NJ; Wiechno, PJ	1
Arnulf, B; Bahlis, NJ; Canepa, L; Delforge, M; Eisenmann, JC; Ervin-Haynes, A; Escoffre-Barbe, M; Ezaydi, Y; Facon, T; Fragasso, A; Giraldo-Castellano, P; Guo, S; Houck, V; Langer, C; Lemieux, B; Leyvraz, S; Minuk, L; Monzini, MS; Song, K; Vogl, DT; Yoon, SS; Zarnitsky, C	1
Allred, J; Bergsagel, PL; Buadi, FK; Dispenzieri, A; Fonseca, R; Gertz, MA; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Rajkumar, SV; Reeder, CB; Rivera, CE; Roy, V; Stewart, AK	1
Beksac, M; Bringhen, S; Fıratlı-Tuğlular, T; Gimsing, P; Juliusson, G; Kristinsson, SY; Lupparelli, G; Palumbo, A; Sucak, GT; Turesson, I; Waage, A	1
Ishida, T	1
Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK	1
Cejalvo, MJ; de la Rubia, J	1
Liaw, BC; Oh, WK	1
McCormack, PL	1
Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M	1
Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, L; Kapoor, P; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Majithia, N; Russell, SJ; Vincent Rajkumar, S	1
Benevolo, G; Boccadifuoco, L; Boccadoro, M; Caravita, T; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Donato, F; Gay, F; Guglielmelli, T; Hajek, R; Hardan, I; Jacques, C; Larocca, A; Musto, P; Nagler, A; Nozzoli, C; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Vincelli, D; Yu, Z	1
Fairley, JK; Leon, KE; McDonald, RW; Salinas, JL; Sheth, AN	1
Kusec, R; Livun, A; Manshouri, T; Newberry, KJ; Verstovsek, S	1
Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI	1
Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W	1
Holstein, SA; McCarthy, PL	1
Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A	1
Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R	1
Hellmich, M; Kuhr, K; Lehmacher, W; Srivastava, K; Wirth, D	1
Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB	1
Adesunloye, BA; Arlen, PM; Beedie, SL; Chen, C; Chun, G; Cordes, L; Couvillon, A; Dahut, WL; Dawson, NA; Figg, WD; Gulley, JL; Harold, N; Huang, X; Karzai, FH; Lee, MJ; Lee, S; Madan, RA; McLeod, DG; Ning, YM; Rosner, I; Sissung, T; Steinberg, SM; Theoret, MR; Tomita, Y; Trepel, JB	1
Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S	1
Ding, ZX; Li, BY; Lyu, WW; Song, DH; Wei, CM; Zhang, JJ; Zhao, QC	1
Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A	1
Yang, YZ	1
Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S	1
Chiappella, A; Flament, J; Gascoyne, RD; Nowakowski, GS; Repici, J; Spina, M; Vitolo, U; Witzig, TE; Zhang, L	1
Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB	1
Azais, I; Belch, A; Chen, G; Dakhil, S; Dimopoulos, MA; Doyen, C; Dührsen, U; Eek, R; Ervin-Haynes, A; Facon, T; Garderet, L; Gisslinger, H; Goncalves, C; Houck, V; Hulin, C; Hunter, H; LeBlanc, R; Leleu, X; Leupin, N; Lu, J; Macro, M; Offner, F; Pégourié, B; Petrucci, MT; Rodon, P; Romeril, K; Royer, B; Shustik, C; Song, K	1
Bahlis, NJ; Chen, BE; Chen, C; Djurfeldt, M; Han, M; Hay, AE; Howsen-Jan, K; Meyer, RM; Murugesan, A; Reece, D; Reiman, T; Seftel, MD; Shepherd, L; Song, K; Stewart, K; White, D; Xie, Y; Zhu, L	1
Liu, HB; Wang, W	1
Chihara, D; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kantarjian, H; Maeng, H; Masarova, L; Newberry, KJ; Ravandi, F; Verstovsek, S	1
Chan, TS; Khong, PL; Kwong, YL	1
Barton, D; Bellmunt, J; Berry, WR; Burke, JM; Crane, E; De Wit, R; Doner, K; Fandi, A; Fizazi, K; Gandhi, A; Hainsworth, JD; Hutson, TE; Jungnelius, U; Liu, K; Petrylak, DP; Sternberg, CN; Vogelzang, NJ; Waldman, MF; Wiechno, PJ	1
Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Morrée, ES; de Wit, R; Doner, K; Fandi, A; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, JS; Li, S; Ochoa de Olza, M; Petrylak, DP; Sternberg, CN; van As, N; Vogelzang, NJ; Wiechno, PJ	1
Deng, M; Peng, H; Yin, Y; Zhang, G	1
Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Levin, MD; Lokhorst, HM; Mutis, T; Nijhof, IS; Oostvogels, R; Raymakers, R; Sonneveld, P; van de Donk, NWCJ; van der Spek, E; van Kessel, B; van Spronsen, DJ; van Velzen, J; Westerweel, PE; Ypma, PF; Zweegman, S	1
Gui, L; He, XH; Liu, P; Qin, Y; Shi, YK; Yang, JL; Yang, S; Zhang, CG; Zhou, SY	1
Guo, C; He, P; Sun, C; Wang, X; Zhang, M	1
Bringhen, S; Di Raimondo, F; Gay, F; Gentile, M; Grazia Recchia, A; Greco, R; Larocca, A; Magarotto, V; Morabito, F; Musto, P; Offidani, M; Palumbo, A; Petrungaro, A; Ria, R; Teresa Petrucci, M; Tripepi, G; Uccello, G; Vigna, E	1
Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS	1
Ko, C; Leventhal, J; Much, M; Stahl, M; Weed, J; Witt, D; Zeidan, AM	1
Bahlis, NJ; Basu, S; Chen, G; Corso, A; de Revel, T; Decaux, O; Demuynck, H; Desjardins, P; Ervin-Haynes, A; Facon, T; Granell, M; Guthrie, TH; Huang, SY; Marek, J; Marit, G; Mugge, LO; Nahi, H; Shen, ZX; Stoppa, AM	1
Bosly, A; Bouabdallah, R; Briere, J; Caballero, D; Cabeçadas, J; Casasnovas, RO; Catalano, J; Choufi, B; Cohen, AM; Coiffier, B; Corront, B; Fruchart, C; Gaulard, P; Gomes da Silva, M; Gonzalez, H; Greil, R; Grosicka, A; Haioun, C; Lazarovici, J; Lopez-Guillermo, A; Morschhauser, F; Oberic, L; Perrot, A; Salles, G; Sebban, C; Thieblemont, C; Tilly, H; Trotman, J; van Eygen, K; Van Hoof, A	1
Li, Y; Ren, XY; Sun, F; Wang, P; Wu, QJ; Zeng, XF; Zhao, JL	1
Chang, Y; Duan, W; Fu, X; Li, L; Li, X; Li, Z; Nan, F; Sun, Z; Wang, X; Wu, J; Yan, J; Young, KH; Zhang, L; Zhang, M; Zhang, X	1
Ballanti, S; Bringhen, S; Corvatta, L; Liberati, AM; Offidani, M; Pulini, S	1
Peña, C; Quilodrán, JA; Valladares, X	1
Anderson, KC; Attal, M; Holstein, SA; McCarthy, PL; Richardson, PG; Schlossman, RL	1
Ludwig, H; Zojer, N	1
Bourquard, P; Chevallier, T; Cousin, C; Dubois, F; Favier, M; Favier-Archinard, C; Le Gall, T; Leguelinel-Blache, G; Passemard, N; Rey, A; Rossi, M; Tora, S	1
Li, Y; Liu, Y; Luo, Y; Marion, TN; Wang, Z; Xu, W; Zhao, Y	1
Gilbert, L; Ordway, S; Wanko, S	1
Gordon, LI	1
Becker, S; Bouabdallah, R; Cabeçadas, J; Casasnovas, O; Feugier, P; Gabarre, J; Gouill, SL; Haioun, C; Jardin, F; Lamy, T; Molina, TJ; Morschhauser, F; Mounier, N; Salles, G; Tilly, H; Tournilhac, O	1
da Costa Nery, JA; Pereira Cardozo, MR; Tavares Rodrigues, F	1
Bai, H; Chen, JW; Fan, WJ; Wu, T	1
Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S	1
Han, B; Huang, YH; Li, T; Wang, SJ; Zhou, DB	1
Stone, K; van Rhee, F	1
Abdul-Hay, M; Naymagon, L	1
Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E	1
Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S	1
Cavo, M; Dimopoulos, MA; Facon, T; Gebregergish, SB; Heeg, B; Lam, A; Mateos, MV; Nair, S; Pisini, M; Slavcev, M; van Beekhuizen, S	1
Boechat, AL; das Graças Souza Cunha, M; de Souza Passos, LF; Dos-Santos, MC; Pereira, HLA; Ribeiro, SLE; Sato, EI; Silva, NP	1
Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS	1
Pan, M; Wang, J; Zhang, Y	1
Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D	1
Armesto, S; Gómez-Fernández, C; González López, MA; González Vela, C; González-Gay, MA; Illaro, A; López Sundh, AE; Mayorga, J; Naharro Fernández, C; Palmou, N; Sánchez, J	1
Barete, S; Bouillet, L; Buffier, S; Cacoub, P; Comarmond, C; Fain, O; Gerfaud-Valentin, M; Gobert, D; Goulenok, T; Jamilloux, Y; Lazaro, E; Le Joncour, A; Misery, L; Saadoun, D; Sacre, K; Sève, P; Vautier, M; Vieira, M	1
Brožová, L; Hájek, R; Heindorfer, A; Jelínek, T; Jungová, A; Kessler, P; Maisnar, V; Minařík, J; Pavlíček, P; Pika, T; Pour, L; Radocha, J; Sandecká, V; Ševčíková, S; Špička, I; Starostka, D; Stejskal, L; Štork, M; Straub, J; Sýkora, M; Ullrychová, J; Wróbel, M	1
Despas, F; Gauthier, M; Icard, C; Mocquot, P; Nogaro, JC	1
Akbay, EA; Beckley, NA; Burma, S; Gerber, DE; Gong, K; Guo, G; Habib, AA; Minna, JD; Yang, X; Zhang, Y; Zhao, D	1
Cai, Q; Song, W; Sun, X; Wang, L; Wang, Y; Xue, H; Zhang, H; Zhang, L; Zhang, M; Zou, L	1
Chen, J; Gale, RP; Li, B; Pan, L; Qin, T; Qu, S; Wu, J; Xiao, Z; Xu, Z; Yan, X; Zhang, P; Zhang, Y	1
Bao, S; Chai, G; Chen, X; Liu, C; Mao, J; Zhi, Y; Zhu, J	1
Cheirif-Wolosky, O; Elizalde-Jiménez, IG; Romero, MTG	1
Hou, SL; Li, L; Lian, K; Zhang, QH	1

Reviews

55 review(s) available for prednisone and thalidomide

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[Evaluation and treatment of aphthous ulcerations of the mouth]. Annales de dermatologie et de venereologie, 1991, Volume: 118, Issue:1 Topics: Anti-Infective Agents, Local; Ascorbic Acid; Behcet Syndrome; Colchicine; Diagnosis, Differential; Humans; Inosine Pranobex; Mouthwashes; Prednisone; Stomatitis, Aphthous; Stomatitis, Herpetic; Thalidomide	1991
[Leprosy--current aspects of a disease from biblical times]. Immunitat und Infektion, 1995, Volume: 23, Issue:6 Topics: Bible; Clofazimine; Glucocorticoids; History, Ancient; Humans; Immunotherapy; Leprostatic Agents; Leprosy; Prednisone; Thalidomide	1995
Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1996, Volume: 64, Issue:4 Suppl Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Cyclosporine; Drug Administration Schedule; Erythema Nodosum; Humans; Hypersensitivity, Delayed; Immunosuppressive Agents; Leprostatic Agents; Leprosy; Leprosy, Lepromatous; Peripheral Nervous System Diseases; Prednisolone; Prednisone; Thalidomide	1996
Treatment of myeloma: recent developments. Anti-cancer drugs, 2002, Volume: 13, Issue:4 Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Therapy; Humans; Interferons; Melphalan; Multiple Myeloma; Neoplasm Staging; Netherlands; Prednisone; Stem Cell Transplantation; Thalidomide	2002
[Behcet's disease therapy review]. Anales de medicina interna (Madrid, Spain : 1984), 2002, Volume: 19, Issue:11 Topics: Behcet Syndrome; Colchicine; Dapsone; Humans; Methotrexate; Prednisone; Thalidomide	2002
Pharmacotherapy of multiple myeloma: an economic perspective. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:4 Topics: Aged; Cost-Benefit Analysis; Drug Therapy; Economics, Pharmaceutical; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thalidomide	2003
Modern management of myelofibrosis. British journal of haematology, 2005, Volume: 128, Issue:5 Topics: Adult; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Humans; Middle Aged; Palliative Care; Prednisone; Primary Myelofibrosis; Splenectomy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2005
HIV-related lymphoma treated with maintenance thalidomide. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:3 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Axilla; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Immunotherapy; Lymphatic Irradiation; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Thalidomide; Vincristine	2005
Multiple myeloma: diagnosis and treatment. Mayo Clinic proceedings, 2005, Volume: 80, Issue:10 Topics: Algorithms; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Retreatment; Stem Cell Transplantation; Thalidomide; Translocation, Genetic	2005
Drug therapy for the treatment of Langerhans cell histiocytosis. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:14 Topics: Anti-Inflammatory Agents; Antimetabolites; Brain Diseases; Cell Proliferation; Cladribine; Cytarabine; Drug Therapy, Combination; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Mercaptopurine; Practice Guidelines as Topic; Prednisone; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Thalidomide; Vinblastine	2005
Treatment of multiple myeloma: an emphasis on new developments. Annals of medicine, 2006, Volume: 38, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2006
Therapy and management of systemic AL (primary) amyloidosis. Swiss medical weekly, 2006, Nov-11, Volume: 136, Issue:45-46 Topics: Amyloidosis; Dexamethasone; Glucocorticoids; Humans; Immunosuppressive Agents; Melphalan; Myeloablative Agonists; Prednisone; Stem Cell Transplantation; Thalidomide	2006
Maintenance therapy for multiple myeloma with particular emphasis on thalidomide. Onkologie, 2006, Volume: 29, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Humans; Interferon-alpha; Multiple Myeloma; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prednisone; Thalidomide; Treatment Outcome	2006
Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 9 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2007
Tandem transplants in the treatment of multiple myeloma. Pro. Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	2004
[Therapy of multiple myeloma: indications and options]. Der Internist, 2007, Volume: 48, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden	2007
Clinical updates and nursing considerations for patients with multiple myeloma. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:6 Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome	2007
Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Best practice & research. Clinical haematology, 2007, Volume: 20, Issue:4 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Thalidomide	2007
Frontline treatment of multiple myeloma in elderly patients. Blood reviews, 2008, Volume: 22, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide	2008
Advances in therapy of multiple myeloma. Current opinion in oncology, 2008, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome	2008
Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature. Journal of drugs in dermatology : JDD, 2009, Volume: 8, Issue:8 Topics: Adult; Drug Therapy, Combination; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Prednisone; Pulmonary Embolism; Thalidomide; Venous Thrombosis	2009
New treatments for myeloma. Joint bone spine, 2010, Volume: 77, Issue:1 Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide	2010
Post-transplant lymphoproliferative disorder presenting as multiple myeloma. American journal of hematology, 2010, Volume: 85, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diabetic Nephropathies; Disease Progression; Epstein-Barr Virus Infections; Fatal Outcome; Ganciclovir; Humans; Immunosuppressive Agents; Kidney Transplantation; Lumbar Vertebrae; Lymphoproliferative Disorders; Male; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Pancreas Transplantation; Plasmacytoma; Postoperative Complications; Prednisone; Reoperation; Rituximab; Spinal Neoplasms; Tacrolimus; Thalidomide	2010
Thalidomide and lenalidomide in primary myelofibrosis. The Netherlands journal of medicine, 2010, Volume: 68, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Hematopoiesis; Humans; Janus Kinase 2; Lenalidomide; Prednisone; Primary Myelofibrosis; Thalidomide	2010
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. American journal of hematology, 2011, Volume: 86, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2011
Multiple myeloma in the elderly: when to treat, when to go to transplant. Oncology (Williston Park, N.Y.), 2010, Volume: 24, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Transplantation, Autologous	2010
[New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome]. Revue neurologique, 2011, Volume: 167, Issue:1 Topics: Amyloid; Amyloid Neuropathies; Biomarkers; Biopsy; Castleman Disease; Combined Modality Therapy; Drug Therapy, Combination; Early Diagnosis; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin lambda-Chains; Melphalan; Paraproteinemias; Peripheral Nerves; POEMS Syndrome; Prednisone; Salivary Glands, Minor; Skin; Thalidomide; Vascular Endothelial Growth Factor A	2011
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia, 2011, Volume: 25, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Transplants; Treatment Outcome	2011
Treatment of newly diagnosed myeloma in patients not eligible for transplantation. Current hematologic malignancy reports, 2011, Volume: 6, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome	2011
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2011
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood, 2011, Aug-04, Volume: 118, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide	2011
Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert review of hematology, 2012, Volume: 5, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide	2012
New developments in the management of diffuse large B-cell lymphoma. Hematology (Amsterdam, Netherlands), 2012, Volume: 17 Suppl 1 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Vincristine; Vindesine	2012
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome	2012
Induction therapy for newly diagnosed multiple myeloma. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous	2013
Part II: role of maintenance therapy in transplant-ineligible patients. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Jan-01, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine	2013
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation. Hematology/oncology clinics of North America, 2014, Volume: 28, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2014
Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Duodenum; Epirubicin; Fatal Outcome; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Prednisone; Pyrazines; Remission Induction; Stomach; Thalidomide; Tomography, X-Ray Computed; Vincristine	2014
[Standard of care and new drugs for diffuse large B-cell lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Adenine; Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Discovery; Epigenesis, Genetic; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Mice; Molecular Targeted Therapy; Piperidines; Prednisolone; Prednisone; Pyrazoles; Pyrimidines; Radiotherapy, Adjuvant; Rituximab; Thalidomide; Vincristine; Vindesine	2014
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide	2014
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine	2015
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. Future oncology (London, England), 2015, Volume: 11, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Thalidomide	2015
Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation. Drugs & aging, 2015, Volume: 32, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide; Treatment Outcome	2015
Maintenance therapy for multiple myeloma in the era of novel agents. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematology; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2015
First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany. European journal of clinical pharmacology, 2016, Volume: 72, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Germany; Humans; Melphalan; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Thalidomide	2016
Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis. Chinese medical journal, 2016, Feb-05, Volume: 129, Issue:3 Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Thalidomide	2016
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. Vnitrni lekarstvi, 2016, Volume: 62, Issue:1 Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin M; Lenalidomide; Lymphatic Diseases; Neoplasm Recurrence, Local; Piperidines; Prednisone; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Rituximab; Splenomegaly; Thalidomide; Thrombocytopenia; Vincristine; Waldenstrom Macroglobulinemia	2016
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:18 Topics: Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Transplantation, Autologous; Vorinostat	2017
Fixed duration vs continuous therapy in multiple myeloma. Hematology. American Society of Hematology. Education Program, 2017, 12-08, Volume: 2017, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Disease-Free Survival; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Rate; Thalidomide; Time Factors	2017
[Research and Applications Progress of Lenalidomide for Myelofibrosis--Review]. Zhongguo shi yan xue ye xue za zhi, 2018, Volume: 26, Issue:6 Topics: Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide	2018
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. Haematologica, 2019, Volume: 104, Issue:5 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide; Treatment Outcome	2019
Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. Journal of medical case reports, 2019, May-22, Volume: 13, Issue:1 Topics: Aged; Bortezomib; Dexamethasone; Fatigue; Humans; Lymph Nodes; Lymphadenopathy; Male; Plasma Cells; Plasmacytoma; Prednisone; Remission Induction; Thalidomide	2019
Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Male; Neoplasm Recurrence, Local; Pharmacovigilance; Prednisone; Rituximab; Thalidomide	2022
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis. Hematology (Amsterdam, Netherlands), 2022, Volume: 27, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide	2022

Trials

95 trial(s) available for prednisone and thalidomide

Article	Year
Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood, 1995, Nov-01, Volume: 86, Issue:9 Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Constipation; Cyclosporine; Drug Eruptions; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Infections; Leukemia; Male; Middle Aged; Neuritis; Neutropenia; Prednisone; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome	1995
Effect of zafirlukast on leprosy reactions. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1999, Volume: 67, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clofazimine; Cohort Studies; Dapsone; Erythema Nodosum; Female; Humans; Indoles; Leprostatic Agents; Leprosy; Leukotriene Antagonists; Male; Middle Aged; Nerve Degeneration; Phenylcarbamates; Prednisone; Rifampin; Sulfonamides; Thalidomide; Tosyl Compounds	1999
Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood, 2000, Dec-01, Volume: 96, Issue:12 Topics: Actuarial Analysis; Chronic Disease; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Graft vs Host Disease; Humans; Hypesthesia; Neutropenia; Prednisone; Thalidomide	2000
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2001, Volume: 7, Issue:5 Topics: Bone Marrow Transplantation; Chronic Disease; Cyclosporine; Drug Therapy, Combination; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Prednisone; Prognosis; Risk Factors; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Homologous; Treatment Outcome	2001
Thromboembolic events during treatment with thalidomide. Blood, 2002, Jun-01, Volume: 99, Issue:11 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Prednisone; Rituximab; Thalidomide; Thromboembolism; Vincristine	2002
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 2003, Apr-01, Volume: 101, Issue:7 Topics: Adrenal Cortex Hormones; Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoiesis, Extramedullary; Humans; Male; Middle Aged; Pancytopenia; Prednisone; Primary Myelofibrosis; Splenomegaly; Technetium Tc 99m Sulfur Colloid; Thalidomide; Treatment Outcome	2003
[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. Acta leprologica, 2003, Volume: 12, Issue:3 Topics: Adolescent; Adult; Erythema Nodosum; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppressive Agents; Leprostatic Agents; Leprosy, Lepromatous; Male; Neuralgia; Pentoxifylline; Prednisone; Recurrence; Remission Induction; Safety; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-alpha	2003
Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Middle Aged; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Outcome	2004
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet (London, England), 2006, Mar-11, Volume: 367, Issue:9513 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide	2006
The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2006, Volume: 23, Issue:1 Topics: Adrenal Cortex Hormones; Black or African American; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Pilot Projects; Prednisone; Prospective Studies; Quality of Life; Sarcoidosis, Pulmonary; Surveys and Questionnaires; Thalidomide; Time Factors; Treatment Outcome; White People	2006
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 2007, Apr-01, Volume: 109, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide	2007
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. The oncologist, 2007, Volume: 12, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Thalidomide; Treatment Outcome	2007
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-01, Volume: 25, Issue:28 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide	2007
A new standard of care for elderly patients with myeloma. Lancet (London, England), 2007, Oct-06, Volume: 370, Issue:9594 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Delivery of Health Care; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Survival Rate; Thalidomide	2007
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet (London, England), 2007, Oct-06, Volume: 370, Issue:9594 Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Survival Rate; Thalidomide	2007
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood, 2008, Oct-15, Volume: 112, Issue:8 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Follow-Up Studies; Humans; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2008
Update on recent developments for patients with newly diagnosed multiple myeloma. Annals of the New York Academy of Sciences, 2008, Volume: 1138 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome	2008
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clinical lymphoma & myeloma, 2009, Volume: 9, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Thrombocytopenia	2009
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Probability; Proportional Hazards Models; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Thalidomide; Treatment Outcome	2009
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-20, Volume: 27, Issue:21 Topics: Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Thalidomide; Time Factors; Transplantation, Autologous	2009
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27 Topics: Adult; Aged; Aged, 80 and over; Anemia; Double-Blind Method; Female; Glucocorticoids; Hematinics; Humans; Immunologic Factors; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Prospective Studies; Thalidomide	2009
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Glucocorticoids; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Neutropenia; Platelet-Derived Growth Factor; Prednisone; Primary Myelofibrosis; Thalidomide; Thrombocytopenia; Transforming Growth Factor beta; Treatment Outcome	2009
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-10, Volume: 28, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome	2010
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica, 2010, Volume: 95, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Melphalan; Multiple Myeloma; Polydeoxyribonucleotides; Prednisone; Salvage Therapy; Thalidomide; Treatment Outcome	2010
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer, 2010, Jun-01, Volume: 116, Issue:11 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neovascularization, Pathologic; Prednisone; Procarbazine; Quality of Life; Recurrence; Rituximab; Thalidomide; Treatment Outcome	2010
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-20, Volume: 28, Issue:12 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Down-Regulation; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Mice; Mice, SCID; Middle Aged; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; Time Factors; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays	2010
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia, 2010, Volume: 24, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome	2010
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood, 2010, Jul-15, Volume: 116, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Dexamethasone; Disease-Free Survival; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proportional Hazards Models; Regulatory Factor X Transcription Factors; Thalidomide; Transcription Factors; Vincristine; X-Box Binding Protein 1	2010
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood, 2010, Sep-02, Volume: 116, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Male; Melphalan; Multiple Myeloma; Placebos; Prednisone; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome	2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neutropenia; Pain; Prednisone; Quality of Life; Regression Analysis; Thalidomide; Treatment Outcome	2010
Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood, 2010, Nov-25, Volume: 116, Issue:22 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Studies; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Thalidomide	2010
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom The Lancet. Oncology, 2010, Volume: 11, Issue:10 Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome	2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-01, Volume: 28, Issue:34 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome	2010
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. European journal of haematology, 2011, Volume: 86, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Female; Humans; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Opportunistic Infections; Prednisone; Survival Analysis; Thalidomide; Treatment Outcome	2011
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Annals of hematology, 2011, Volume: 90, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Models, Statistical; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Surveys and Questionnaires; Thalidomide; Treatment Outcome	2011
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leukemia & lymphoma, 2011, Volume: 52, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide; Treatment Outcome	2011
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia, 2011, Volume: 25, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Rituximab; Survival Rate; Thalidomide; Treatment Outcome; Vincristine	2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood, 2011, Nov-24, Volume: 118, Issue:22 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome	2011
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leukemia & lymphoma, 2012, Volume: 53, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; Indoles; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neutropenia; Panobinostat; Prednisone; Recurrence; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome	2012
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. The New England journal of medicine, 2012, May-10, Volume: 366, Issue:19 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Prednisone; Thalidomide	2012
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood, 2012, Sep-27, Volume: 120, Issue:13 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Maintenance Chemotherapy; Male; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide	2012
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia, 2013, Volume: 27, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Survival Rate; Thalidomide	2013
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2013
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica, 2013, Volume: 98, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Surveys and Questionnaires; Thalidomide	2013
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood, 2013, Feb-28, Volume: 121, Issue:9 Topics: Academies and Institutes; Antineoplastic Combined Chemotherapy Protocols; Canada; Female; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Prednisone; Quality of Life; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome	2013
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica, 2013, Volume: 98, Issue:11 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Doxorubicin; Female; Humans; Italy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine	2013
Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial. Clinical trials (London, England), 2013, Volume: 10, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bayes Theorem; Drug Therapy, Combination; Expert Testimony; Humans; Melphalan; Models, Statistical; Multiple Myeloma; Myeloablative Agonists; Prednisone; Stem Cell Transplantation; Surveys and Questionnaires; Survival Analysis; Thalidomide	2013
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood, 2013, Oct-17, Volume: 122, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Thalidomide; Time Factors; Treatment Outcome	2013
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leukemia & lymphoma, 2014, Volume: 55, Issue:7 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Quality of Life; Thalidomide; Treatment Outcome	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome	2014
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clinical therapeutics, 2014, Apr-01, Volume: 36, Issue:4 Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferative Disorders; Neoplasms; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide; Treatment Outcome	2014
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. European journal of haematology, 2014, Volume: 93, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome	2014
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. The Lancet. Oncology, 2014, Volume: 15, Issue:7 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Vincristine	2014
Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study. Clinical advances in hematology & oncology : H&O, 2014, Volume: 12, Issue:2 Suppl 6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Follicular; Male; Prednisone; Rituximab; Thalidomide; Vincristine	2014
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leukemia research, 2014, Volume: 38, Issue:9 Topics: Aged; Aged, 80 and over; Anemia; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Survival Analysis; Thalidomide; Treatment Outcome	2014
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. Oncology, 2014, Volume: 87, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Disease-Free Survival; Economics, Pharmaceutical; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Thalidomide	2014
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood, 2014, Sep-18, Volume: 124, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2014
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-20, Volume: 33, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Phenotype; Prednisone; Prognosis; Rituximab; Thalidomide; Treatment Outcome; Vincristine	2015
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma. British journal of haematology, 2015, Volume: 168, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Thalidomide; Treatment Outcome	2015
Autologous transplantation and maintenance therapy in multiple myeloma. The New England journal of medicine, 2014, Sep-04, Volume: 371, Issue:10 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous	2014
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. The New England journal of medicine, 2014, Sep-04, Volume: 371, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide	2014
Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. British journal of haematology, 2015, Volume: 168, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Combined Modality Therapy; Factor VIII; Female; Fibrin Fibrinogen Degradation Products; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peptide Hydrolases; Prednisone; Thalidomide; Thrombin; Thrombophilia; Transplantation, Autologous; Venous Thromboembolism	2015
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Placebos; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide	2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica, 2015, Volume: 100, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Dexamethasone; Female; Health Status; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Thalidomide	2015
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Blood cancer journal, 2015, Mar-20, Volume: 5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide	2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood, 2015, Sep-10, Volume: 126, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Quality of Life; Thalidomide	2015
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Oct-20, Volume: 33, Issue:30 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide	2015
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Blood, 2016, Jan-28, Volume: 127, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2016
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:16 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosphamide; Czech Republic; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Risk Factors; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome	2015
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica, 2016, Volume: 101, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome	2016
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood, 2016, Apr-14, Volume: 127, Issue:15 Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide	2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. BJU international, 2016, Volume: 118, Issue:4 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bevacizumab; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Thalidomide	2016
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood, 2016, Mar-03, Volume: 127, Issue:9 Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome; Withholding Treatment	2016
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. British journal of haematology, 2016, Volume: 173, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult	2016
[Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lactate Dehydrogenases; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Prednisone; Survival Rate; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A; Vincristine	2016
ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future oncology (London, England), 2016, Volume: 12, Issue:13 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; Doxorubicin; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Research Design; Rituximab; Thalidomide; Vincristine	2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood, 2016, 06-23, Volume: 127, Issue:25 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Dexamethasone; Drug Monitoring; Female; Humans; Immunity; Lenalidomide; Male; Melphalan; Monitoring, Physiologic; Multiple Myeloma; Neoplasm, Residual; Prednisone; Prognosis; Survival Analysis; Thalidomide; Vincristine	2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 10-20, Volume: 34, Issue:30 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Survival Rate; Thalidomide	2016
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia research, 2016, Volume: 48 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Remission Induction; Thalidomide; Treatment Outcome	2016
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. European urology, 2017, Volume: 71, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Lenalidomide; Male; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thalidomide	2017
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. JAMA oncology, 2017, Jan-01, Volume: 3, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide	2017
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. Blood, 2016, 11-10, Volume: 128, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Thalidomide; Treatment Outcome	2016
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. American journal of hematology, 2017, Volume: 92, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Tumor Burden	2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. British journal of haematology, 2017, Volume: 176, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome	2017
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia, 2017, Volume: 31, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide	2017
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Aug-01, Volume: 35, Issue:22 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Eruptions; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Placebos; Prednisone; Rituximab; Survival Rate; Thalidomide; Vincristine	2017
The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. British journal of haematology, 2017, Volume: 178, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prednisolone; Prednisone; Prospective Studies; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Thalidomide; Treatment Outcome; Vincristine; Young Adult	2017
Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. Leukemia & lymphoma, 2018, Volume: 59, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Prednisone; Prognosis; Survival Rate; Thalidomide	2018
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. The Lancet. Haematology, 2018, Volume: 5, Issue:9 Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Rituximab; Thalidomide; Tumor Burden; Vincristine	2018
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia, 2020, Volume: 34, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Frail Elderly; Frailty; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2020
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica, 2020, Volume: 105, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Thalidomide	2020
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). American journal of hematology, 2020, Volume: 95, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide	2020
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. Cancer medicine, 2020, Volume: 9, Issue:23 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Disease Progression; Drug Administration Schedule; Eligibility Determination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Thalidomide; Time Factors; United States	2020
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial. American journal of hematology, 2022, Volume: 97, Issue:5 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Humans; Lymphoma, T-Cell, Peripheral; Neutropenia; Prednisone; Thalidomide; Treatment Outcome	2022

Other Studies

144 other study(ies) available for prednisone and thalidomide

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Treatment of Hansen's disease. Cutis, 1976, Volume: 18, Issue:1 Topics: Chloroquine; Clofazimine; Dapsone; Drug Resistance, Microbial; Erythema Nodosum; Humans; Leprosy; Prednisone; Rifampin; Thalidomide	1976
Therapy of chronic graft-v-host disease in a rat model. Blood, 1989, Volume: 74, Issue:1 Topics: Animals; Azathioprine; Cyclosporins; Disease Models, Animal; Drug Synergism; Graft vs Host Disease; Immunosuppressive Agents; Prednisone; Rats; Rats, Inbred Strains; Thalidomide; Time Factors	1989
The clinical significance of erythema nodosum. Hospital practice (Office ed.), 1986, Mar-15, Volume: 21, Issue:3 Topics: Adult; Anti-Inflammatory Agents; Antigen-Antibody Complex; Coccidioidomycosis; Diagnosis, Differential; Erythema Nodosum; Female; Histoplasmosis; Humans; Leprosy; Lung Diseases, Fungal; Male; Potassium Iodide; Prednisone; Skin; Thalidomide	1986
Treatment of chronic erythema nodosum leprosum with cyclosporine A produces clinical and immunohistologic remission. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1987, Volume: 55, Issue:3 Topics: Adult; Antibodies, Bacterial; Antigen-Antibody Complex; Chronic Disease; Cyclosporins; Erythema Nodosum; Female; Humans; Leprosy; Leukocyte Count; Male; Middle Aged; Mycobacterium leprae; Prednisone; Skin; T-Lymphocytes; Thalidomide	1987
Thalidomide in the treatment of neuro-Behçet's syndrome. The British journal of dermatology, 1986, Volume: 115, Issue:3 Topics: Adult; Behcet Syndrome; Chlorambucil; Drug Therapy, Combination; Humans; Male; Nervous System Diseases; Prednisone; Thalidomide	1986
Genetical, social, and medical aspects of abortion. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1968, Jul-20, Volume: 42, Issue:28 Topics: Abnormalities, Drug-Induced; Abortion, Criminal; Abortion, Legal; Abortion, Therapeutic; Adolescent; Adult; Aminopterin; Attitude; Chromosome Aberrations; Chromosome Disorders; Congenital Abnormalities; Counseling; Ethics, Medical; Female; Genes, Recessive; Humans; Infant, Newborn; Infant, Newborn, Diseases; Mental Disorders; Middle Aged; Pedigree; Population Control; Prednisone; Pregnancy; Pregnancy Complications; Religion and Medicine; Rubella; South Africa; Thalidomide	1968
Serum macrophage migration inhibition activity in patients with leprosy. The Journal of investigative dermatology, 1982, Volume: 79, Issue:5 Topics: Dapsone; Dinitrochlorobenzene; Humans; Hypersensitivity, Delayed; Leprosy; Macrophage Migration-Inhibitory Factors; Molecular Weight; Muramidase; Prednisone; Thalidomide	1982
Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals. Digestive diseases and sciences, 1995, Volume: 40, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Female; HIV Seropositivity; HIV-1; Humans; Prednisone; Thalidomide; Ulcer; Zidovudine	1995
Thalidomide as replacement for steroids in immunosuppression after lung transplantation. The Annals of thoracic surgery, 1995, Volume: 59, Issue:2 Topics: Animals; Azathioprine; Cyclosporine; Dogs; Graft Rejection; Immunosuppressive Agents; Lung; Lung Transplantation; Pneumonia; Postoperative Complications; Prednisone; Thalidomide; Wound Healing	1995
Chronic cutaneous lupus erythematosus treated with thalidomide. Archives of dermatology, 1993, Volume: 129, Issue:12 Topics: Adult; Alopecia; Female; Humans; Lupus Erythematosus, Discoid; Prednisone; Scalp Dermatoses; Thalidomide	1993
Thalidomide treatment for idiopathic esophageal ulcers in patients with HIV. Gastrointestinal endoscopy, 1996, Volume: 44, Issue:6 Topics: Acquired Immunodeficiency Syndrome; Adult; Endoscopy, Digestive System; Esophageal Diseases; Humans; Male; Prednisone; Thalidomide; Ulcer	1996
A clinical study on severe hydroa vacciniforme. Chinese medical journal, 1996, Volume: 109, Issue:8 Topics: Adolescent; Adult; Anti-Inflammatory Agents; Drugs, Chinese Herbal; Female; Humans; Hydroa Vacciniforme; Immunosuppressive Agents; Male; Prednisone; Thalidomide; Tripterygium	1996
Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1998, Volume: 66, Issue:1 Topics: Adolescent; Adult; Cytokines; Erythema Nodosum; Female; Humans; Leprosy, Lepromatous; Male; Pentoxifylline; Prednisone; Receptors, Cytokine; Thalidomide	1998
Steroid-resistant idiopathic esophageal ulcer in a child with AIDS. Journal of pediatric gastroenterology and nutrition, 1998, Volume: 27, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Candidiasis; Child, Preschool; Drug Resistance; Esophageal Diseases; Female; Humans; Hydrocortisone; Prednisone; Recurrence; Steroids; Thalidomide; Ulcer	1998
Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. Journal of the American Academy of Dermatology, 1998, Volume: 39, Issue:5 Pt 2 Topics: Dermatologic Agents; Drug Administration Schedule; Facial Dermatoses; Female; Fingers; Glucocorticoids; Humans; Leg; Middle Aged; Nose Diseases; Orbital Diseases; Paresthesia; Prednisone; Sarcoidosis; Skin Diseases; Thalidomide	1998
Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. Seminars in oncology, 2001, Volume: 28, Issue:6 Topics: Adult; Angiogenesis Inhibitors; Drug Therapy, Combination; Female; Glucocorticoids; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Remission Induction; Thalidomide	2001
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone marrow transplantation, 2002, Volume: 29, Issue:7 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Autologous; Vincristine	2002
Decreases in mean hemoglobin and serum albumin values in erythema nodosum leprosum and lepromatous leprosy. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 2001, Volume: 69, Issue:4 Topics: Anemia; Dapsone; Erythema Nodosum; Hemoglobins; Humans; Leprostatic Agents; Leprosy, Lepromatous; Prednisone; Retrospective Studies; Serum Albumin; Thalidomide	2001
Differential TNFalpha mRNA regulation detected in the epidermis of leprosy patients. Archives of dermatological research, 2002, Volume: 294, Issue:8 Topics: Adult; Aged; Anti-Inflammatory Agents; Cytokines; Dermis; Epidermis; Female; Humans; Intercellular Adhesion Molecule-1; Leprostatic Agents; Leprosy; Male; Middle Aged; Pentoxifylline; Prednisone; RNA, Messenger; Thalidomide; Tumor Necrosis Factor-alpha	2002
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire? Leukemia research, 2003, Volume: 27, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia	2003
Innovative strategies in lymphoma therapy. Wiener klinische Wochenschrift, 2003, Aug-14, Volume: 115, Issue:13-14 Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine	2003
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Annals of hematology, 2004, Volume: 83, Issue:7 Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Humans; Idarubicin; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Thalidomide; Vasculitis, Leukocytoclastic, Cutaneous; Vincristine	2004
Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Leukemia & lymphoma, 2003, Volume: 44, Issue:11 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Salvage Therapy; Thalidomide; Treatment Outcome; Vincristine	2003
Generalized eruptive histiocytosis: a possible therapeutic cure? The British journal of dermatology, 2004, Volume: 150, Issue:1 Topics: Adult; Dermatologic Agents; Drug Therapy, Combination; Facial Dermatoses; Histiocytosis, Langerhans-Cell; Humans; Hydroxychloroquine; Male; Prednisone; Thalidomide	2004
Refractory major aphthous stomatitis managed with systemic immunosuppressants: a case report. Quintessence international (Berlin, Germany : 1985), 2004, Volume: 35, Issue:1 Topics: Adult; Clinical Protocols; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Patient Education as Topic; Prednisone; Recurrence; Stomatitis, Aphthous; Thalidomide	2004
Hb H disease and multiple myeloma. Hemoglobin, 2004, Volume: 28, Issue:1 Topics: Aged; alpha-Thalassemia; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Female; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisone; Splenectomy; Thalidomide	2004
Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clinic proceedings, 2004, Volume: 79, Issue:7 Topics: Adult; Aged; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Thalidomide; Treatment Outcome	2004
Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy. International journal of dermatology, 2004, Volume: 43, Issue:9 Topics: Azathioprine; Diagnosis, Differential; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Middle Aged; Pemphigus; Prednisone; Thalidomide; Uterine Cervical Diseases	2004
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Platelet Transfusion; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Recurrence; Thalidomide	2004
Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:4 Topics: Age Factors; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Drug Therapy, Combination; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide	2005
Schnitzler's syndrome without monoclonal gammopathy. Acta dermato-venereologica, 2005, Volume: 85, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diagnosis, Differential; Drug Therapy, Combination; Humans; Immunoglobulin M; Male; Prednisone; Syndrome; Thalidomide; Urticaria	2005
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer, 2005, Oct-01, Volume: 104, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome	2005
Current treatment of myelofibrosis. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:4 Topics: Blood Transfusion; Bone Marrow Transplantation; Clinical Trials as Topic; Dexamethasone; Disease Management; Drug Therapy, Combination; Esophageal and Gastric Varices; Farnesyltranstransferase; Gastrointestinal Hemorrhage; Hematopoietic Cell Growth Factors; Humans; Lenalidomide; Prednisone; Primary Myelofibrosis; Quinazolines; Spleen; Splenectomy; Thalidomide; Transplantation, Homologous	2005
Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. Haematologica, 2005, Volume: 90, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Survival Analysis; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation	2005
Thalidomide for the treatment of leptomeningeal multiple myeloma. European journal of haematology, 2006, Volume: 76, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunoglobulin G; Melphalan; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisolone; Prednisone; Thalidomide; Vindesine	2006
Thalidomide gives food for thought in multiple myeloma. The Lancet. Oncology, 2006, Volume: 7, Issue:4 Topics: Adult; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Risk Factors; Survival Analysis; Thalidomide; Venous Thrombosis	2006
Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. Acta oto-laryngologica, 2006, Volume: 126, Issue:5 Topics: Acute Disease; Audiometry, Evoked Response; Autoimmune Diseases; C-Reactive Protein; Diagnosis, Differential; Diuretics, Osmotic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ear Diseases; Ear, External; Endolymphatic Hydrops; Female; Hearing Loss, Sensorineural; Humans; Immunoglobulin M; Immunosuppressive Agents; Isosorbide; Meniere Disease; Middle Aged; Polychondritis, Relapsing; Prednisone; Primary Myelofibrosis; Thalidomide; Treatment Outcome	2006
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:8 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxaparin; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk; Thalidomide; Thromboembolism; Time Factors	2006
Advances in the treatment of elderly patients with multiple myeloma. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide	2006
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL. Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous	2007
Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly. Haematologica, 2007, Volume: 92, Issue:2 Topics: Aged, 80 and over; Angiogenesis Inhibitors; Blood Transfusion; Bone Marrow; Combined Modality Therapy; Drug Therapy, Combination; Fluoxymesterone; Folic Acid; Humans; Male; Prednisone; Primary Myelofibrosis; Remission Induction; Splenomegaly; Thalidomide; Vitamin B Complex	2007
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. American journal of hematology, 2007, Volume: 82, Issue:10 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histiocytes; Humans; Middle Aged; Prednisone; Retroperitoneal Neoplasms; Sarcoma; Thalidomide; Vincristine	2007
Refractory multiple myeloma treated with homoharringtonine: report of two cases. Annals of hematology, 2007, Volume: 86, Issue:12 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine	2007
Clinical, immunological and histological aspects of an uncommon type II reaction in patients with lepromatous leprosy. Clinical and experimental dermatology, 2008, Volume: 33, Issue:3 Topics: Aged; Antiviral Agents; Erythema Nodosum; Humans; Interferon-gamma; Leprosy, Lepromatous; Male; Middle Aged; Mycobacterium leprae; Prednisone; T-Lymphocytes; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-alpha	2008
Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer, 2008, Apr-01, Volume: 112, Issue:7 Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Incidence; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prednisone; Risk Factors; Survival Rate; Thalidomide; Venous Thrombosis	2008
Bortezomib plus melphalan and prednisone for multiple myeloma. The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2008
Bortezomib plus melphalan and prednisone for multiple myeloma. The New England journal of medicine, 2008, Dec-11, Volume: 359, Issue:24 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide	2008
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. International journal of hematology, 2009, Volume: 89, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis; Hepatic Artery; Humans; Immunoglobulin Light Chains; Ischemia; Lenalidomide; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Thalidomide	2009
Cutaneous involvement in multiple myeloma and bortezomib. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia	2009
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:5 Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; Etoposide; Factor V; Follow-Up Studies; Humans; Hyperhomocysteinemia; Multiple Myeloma; Prednisone; Pulmonary Embolism; Retrospective Studies; Thalidomide; Thrombophilia; Venous Thrombosis	2009
Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment. Prescrire international, 2009, Volume: 18, Issue:100 Topics: Aged; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Europe; Female; Humans; Male; Melphalan; Multiple Myeloma; Orphan Drug Production; Prednisone; Survival; Thalidomide	2009
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Combined Modality Therapy; Comorbidity; Creatinine; Dexamethasone; Doxorubicin; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Retrospective Studies; Risk Assessment; Thalidomide; Treatment Outcome; Vincristine	2009
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. European journal of haematology, 2010, Volume: 84, Issue:3 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine	2010
Treatment of multiple myeloma: 2009 update. Prescrire international, 2009, Volume: 18, Issue:104 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine	2009
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Annals of hematology, 2010, Volume: 89, Issue:8 Topics: Aged; Consensus; Europe; Guidelines as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Risk Factors; Survival Rate; Thalidomide; Thromboembolism	2010
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. European journal of haematology, 2010, Volume: 85, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome	2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. Leukemia & lymphoma, 2010, Volume: 51, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Polyethylene Glycols; Prednisone; Survival Rate; Thalidomide; Treatment Outcome	2010
Frontline regimens for multiple myeloma patients. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:5 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2010
Optimising bortezomib in newly diagnosed multiple myeloma. The Lancet. Oncology, 2010, Volume: 11, Issue:10 Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome	2010
[Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Immunoblastic Lymphadenopathy; L-Lactate Dehydrogenase; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Pneumonia; Prednisone; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thalidomide; Vincristine	2010
First-line treatment of elderly multiple myeloma patients. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide	2010
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation. Annals of hematology, 2011, Volume: 90, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Prednisone; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous	2011
International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. American journal of hematology, 2011, Volume: 86, Issue:1 Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Retrospective Studies; Thalidomide; Treatment Outcome	2011
Recent advances in myeloma treatment. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2011, Volume: 44, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide	2011
History of multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane	2011
[Study to castrate-resistant prostate cancer: AUO study AP 60/10]. Der Urologe. Ausg. A, 2011, Volume: 50, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Humans; Lenalidomide; Male; Prednisone; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Failure	2011
Scleromyxedema with monoclonal gammopathy and neurological involvement: recovery from coma after plasmapheresis? International journal of dermatology, 2012, Volume: 51, Issue:8 Topics: Brain Diseases; Coma; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Myeloablative Agonists; Paraproteinemias; Plasmapheresis; Prednisone; Scleromyxedema; Thalidomide; Treatment Outcome	2012
Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. Journal of pediatric gastroenterology and nutrition, 2012, Volume: 54, Issue:1 Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Blood Sedimentation; Child; Child, Preschool; Constriction, Pathologic; Crohn Disease; Disease Progression; Female; Fistula; Hospitalization; Humans; Hypersensitivity, Immediate; Immunosuppressive Agents; Infliximab; Intestines; Male; Outcome Assessment, Health Care; Peripheral Nervous System Diseases; Prednisone; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome	2012
Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases. Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:2 Topics: Adult; Biopsy, Needle; Castleman Disease; Diagnosis, Differential; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperpigmentation; Immunohistochemistry; Middle Aged; Prednisone; Risk Assessment; Sampling Studies; Severity of Illness Index; Thalidomide; Time Factors; Treatment Outcome	2011
[Efficacy of thalidomide for treatment of juvenile idiopathic arthritis]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2011, Volume: 13, Issue:8 Topics: Adolescent; Arthritis, Juvenile; Child; Female; Humans; Male; Prednisone; Retrospective Studies; Thalidomide	2011
Lepromatous leprosy presenting as an acute polyarthritis in a Colombian immigrant in Spain. Joint bone spine, 2012, Volume: 79, Issue:2 Topics: Acute Disease; Adult; Arthritis; Biopsy; Colombia; Emigration and Immigration; Humans; Leprostatic Agents; Leprosy, Lepromatous; Lymph Nodes; Male; Mycobacterium leprae; Prednisone; Skin; Spain; Thalidomide; Treatment Outcome	2012
[Pyoderma gangrenosum and Behçet's disease: a study of two pediatric cases]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2011, Volume: 18, Issue:12 Topics: Adolescent; Behcet Syndrome; Child; Dermatologic Agents; Drug Therapy, Combination; Fatal Outcome; Female; Glucocorticoids; Humans; Male; Pedigree; Prednisone; Prognosis; Pulmonary Edema; Pyoderma Gangrenosum; Recurrence; Thalidomide	2011
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine	2012
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients. Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:2 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fluorouracil; Follow-Up Studies; Humans; Male; Prednisone; Prostatic Neoplasms; Retrospective Studies; Thalidomide	2012
Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis. Experimental hematology, 2012, Volume: 40, Issue:4 Topics: Agranulocytosis; Alleles; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Models, Animal; Erythrocyte Indices; Erythropoiesis; Gene Expression Regulation, Developmental; Hemoglobins; Heterozygote; Lenalidomide; Lymphopenia; Mice; Mice, Inbred C57BL; Prednisone; Ribosomal Protein S6; Ribosomal Proteins; Ribosomes; RNA-Binding Proteins; Thalidomide; Thrombocytosis	2012
Is the low-thalidomide dose MPT regimen beneficial? The Korean journal of internal medicine, 2011, Volume: 26, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Humans; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2011
A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma. The Korean journal of internal medicine, 2011, Volume: 26, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Confidence Intervals; Disease Progression; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Risk; Thalidomide; Time Factors; Treatment Outcome	2011
Drug interaction between lenalidomide and itraconazole. American journal of hematology, 2012, Volume: 87, Issue:3 Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Female; Humans; Intestinal Absorption; Itraconazole; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide	2012
Lenalidomide in myeloma--a high-maintenance friend. The New England journal of medicine, 2012, May-10, Volume: 366, Issue:19 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide	2012
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematological oncology, 2013, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Chromosome Aberrations; Chromosomes, Human, Pair 1; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Gene Amplification; Hemoglobins; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Prednisone; Prognosis; Remission Induction; Thalidomide	2013
[Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:190 Topics: Amyloidosis; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Immunologic Factors; Lenalidomide; Melphalan; Prednisone; Pyrazines; Thalidomide	2012
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia, 2013, Volume: 27, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine	2013
Lenalidomide for multiple myeloma. The New England journal of medicine, 2012, 08-09, Volume: 367, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide	2012
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass. Clinical neurology and neurosurgery, 2013, Volume: 115, Issue:6 Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Brain Edema; Cerebellar Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nervous System Diseases; Neurosurgical Procedures; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia	2013
Recurrent aortic aneurysm due to Behcet's disease: a case report from China. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2013, Volume: 19, Issue:2 Topics: Adult; Anticoagulants; Aortic Aneurysm; Aortography; Aspirin; Behcet Syndrome; China; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Prednisone; Recurrence; Thalidomide; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2013
How to select among available options for the treatment of multiple myeloma. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome	2012
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up. Hematological oncology, 2013, Volume: 31, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drugs, Investigational; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Organoplatinum Compounds; Polyethylene Glycols; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vinblastine; Vinorelbine	2013
Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. European journal of haematology, 2013, Volume: 90, Issue:2 Topics: Antineoplastic Agents, Hormonal; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Male; Middle Aged; Prednisone; Remission Induction; Thalidomide	2013
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan The oncologist, 2013, Volume: 18, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States	2013
[Six years relapse-free treatment of a case with Langerhans cell histiocytosis grade III treated with thalidomide and prednisone]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2012, Volume: 50, Issue:11 Topics: Administration, Oral; Adolescent; Female; Histiocytosis, Langerhans-Cell; Humans; Lymph Nodes; Prednisone; Retrospective Studies; Skin Ulcer; Thalidomide; Treatment Outcome	2012
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma. British journal of haematology, 2013, Volume: 162, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy	2013
[New treatment strategies for multiple myeloma]. Der Internist, 2013, Volume: 54, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide	2013
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. Leukemia research, 2013, Volume: 37, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult	2013
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology, 2013, Volume: 85, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome	2013
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients. European journal of haematology, 2014, Volume: 92, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retreatment; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome	2014
"A fortuitous combination of circumstances". Blood, 2013, Oct-17, Volume: 122, Issue:16 Topics: Cyclophosphamide; Female; Humans; Male; Multiple Myeloma; Prednisone; Thalidomide	2013
[Crystalline keratopathy due to kappa chains in a monoclonal gammopathy]. Archivos de la Sociedad Espanola de Oftalmologia, 2013, Volume: 88, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Combined Modality Therapy; Corneal Opacity; Crystallization; Cyclophosphamide; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin kappa-Chains; Kidney Failure, Chronic; Lenalidomide; Male; Melphalan; Middle Aged; Paraproteinemias; Paraproteins; Phacoemulsification; Postoperative Complications; Prednisone; Slit Lamp; Thalidomide	2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. American journal of hematology, 2014, Volume: 89, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome	2014
Mucocutaneous ulceration in a previously healthy man. The Journal of family practice, 2014, Volume: 63, Issue:2 Topics: Adult; Behcet Syndrome; Crohn Disease; Diagnosis, Differential; Erythema Multiforme; Herpes Simplex; Humans; Male; Oral Ulcer; Prednisone; Thalidomide	2014
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymph Nodes; Lymphoma, T-Cell; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Recurrence; Retreatment; Thalidomide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine	2014
Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study. Acta clinica Belgica, 2014, Volume: 69, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide	2014
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:5 Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide	2014
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression. International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:7 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine	2014
[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:8 Topics: Adult; Aged; Anemia; Danazol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult	2014
[Suspected itchy rash secondary to lenalidomide]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2014, Nov-03, Volume: 38, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Drug Eruptions; Exanthema; Female; Humans; Lenalidomide; Prednisone; Thalidomide	2014
R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma. Clinical advances in hematology & oncology : H&O, 2014, Volume: 12, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Prednisone; Rituximab; Thalidomide; Vincristine	2014
The MAINSAIL trial: an expected failure. The Lancet. Oncology, 2015, Volume: 16, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide	2015
Does low-molecular-weight heparin influence the antimyeloma effects of thalidomide? A retrospective analysis of data from the GIMEMA, Nordic and Turkish myeloma study groups. Acta haematologica, 2015, Volume: 133, Issue:4 Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome; Turkey	2015
[Complications and managements in treatment of melphalan, prednisone and new agents]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide	2015
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities. Acta haematologica, 2015, Volume: 134, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide	2015
Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs? Nature reviews. Clinical oncology, 2015, Volume: 12, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide	2015
Outcomes of primary refractory multiple myeloma and the impact of novel therapies. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Immunologic Factors; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Proteasome Inhibitors; Radiography; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome	2015
Complex Type 2 Reactions in Three Patients with Hansen's Disease from a Southern United States Clinic. The American journal of tropical medicine and hygiene, 2015, Volume: 93, Issue:5 Topics: Adult; Aged; Anti-Inflammatory Agents; Asia, Southeastern; Bangladesh; Erythema Nodosum; Female; Georgia; Humans; Hypersensitivity; Leprostatic Agents; Leprosy, Lepromatous; Male; Neuritis; Prednisone; Thalidomide	2015
Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3. Anticancer research, 2015, Volume: 35, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Clinical Trials, Phase II as Topic; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Primary Myelofibrosis; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thalidomide	2015
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. Journal of medical economics, 2016, Volume: 19, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years; Thalidomide; Treatment Outcome; United States	2016
Continued role for ASCT in multiple myeloma. The Lancet. Oncology, 2015, Volume: 16, Issue:16 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Prednisone; Thalidomide	2015
A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. Blood, 2016, 08-04, Volume: 128, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prednisone; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Transplantation, Autologous	2016
[Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Survival Rate; Thalidomide; Thrombocytopenia; Vincristine	2016
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma. Annals of hematology, 2016, Volume: 95, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Vincristine	2016
Effects of low-dose thalidomide in chronic refractory immune thrombocytopenia and contributions to the dispensation of glucocorticoid dependence. Annals of hematology, 2016, Volume: 95, Issue:12 Topics: Adult; Chronic Disease; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Aged; Platelet Count; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Thalidomide; Treatment Outcome	2016
[Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, Sep-14, Volume: 37, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Herpesvirus 4, Human; HIV Infections; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Plasmablastic Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Thalidomide; Vincristine	2016
Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China. Asia-Pacific journal of clinical oncology, 2017, Volume: 13, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Remission Induction; Retrospective Studies; Thalidomide	2017
Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Annals of hematology, 2017, Volume: 96, Issue:6 Topics: Aged; Blood Transfusion; Comorbidity; Fatal Outcome; Female; Granuloma; Histiocytes; Humans; Lenalidomide; Multiple Organ Failure; Myelodysplastic Syndromes; Neutrophils; Paraneoplastic Syndromes; Prednisone; Thalidomide	2017
[The 456th case: polyarthritis, dry cough, dyspnea on exertion]. Zhonghua nei ke za zhi, 2017, May-01, Volume: 56, Issue:5 Topics: Arthralgia; Arthritis, Rheumatoid; Autoantibodies; Blood Sedimentation; C-Reactive Protein; Cough; Drug Therapy, Combination; Dyspepsia; Dyspnea; Female; Humans; Lung; Lung Diseases, Interstitial; Middle Aged; Multiple Pulmonary Nodules; Physical Exertion; Prednisone; Rheumatoid Factor; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome	2017
[Extramedullary mediastinal plasmacytoma. Report of one case]. Revista medica de Chile, 2017, Volume: 145, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mediastinal Neoplasms; Mediastinoscopy; Melphalan; Plasmacytoma; Prednisone; Thalidomide; Tomography; Treatment Outcome	2017
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation]. Bulletin du cancer, 2018, Volume: 105, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; Hospitals, University; Humans; Lenalidomide; Male; Medication Adherence; Melphalan; Multiple Myeloma; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Prospective Studies; Thalidomide	2018
Successful mesenchymal stem cell treatment of leg ulcers complicated by Behcet disease: A case report and literature review. Medicine, 2018, Volume: 97, Issue:16 Topics: Adalimumab; Behcet Syndrome; Dose-Response Relationship, Drug; Drug Resistance; Drug Substitution; Etanercept; Female; Humans; Immunosuppressive Agents; Leg Ulcer; Mesenchymal Stem Cell Transplantation; Middle Aged; Prednisone; Thalidomide; Treatment Outcome	2018
POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation. BMJ case reports, 2018, Jul-26, Volume: 2018 Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Drug Therapy, Combination; Dyspnea; Fatigue; Female; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Polyneuropathies; Prednisone; Thalidomide	2018
Lenalidomide and R-CHOP in follicular lymphoma: where do we go from here? The Lancet. Haematology, 2018, Volume: 5, Issue:9 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lenalidomide; Lymphoma, Follicular; Prednisone; Rituximab; Thalidomide; Vincristine	2018
Widespread Dermatophytosis in a Patient Treated for Leprosy Type II Reactional State after MDT/WHO-MB Release. The American journal of tropical medicine and hygiene, 2018, Volume: 99, Issue:4 Topics: Antifungal Agents; Brazil; Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Male; Prednisone; Recurrence; Rifampin; Terbinafine; Thalidomide; Tinea; Trichophyton; Young Adult	2018
Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vincristine, and prednisone. The Journal of international medical research, 2019, Volume: 47, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kasabach-Merritt Syndrome; Prednisone; Prognosis; Thalidomide; Vincristine	2019
Storming the Castle with TCP. Blood, 2019, 04-18, Volume: 133, Issue:16 Topics: Castleman Disease; Cyclophosphamide; Humans; Prednisone; Thalidomide; Thyroid Neoplasms	2019
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid Leukemia & lymphoma, 2020, Volume: 61, Issue:3 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome	2020
Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy. Advances in rheumatology (London, England), 2019, 11-28, Volume: 59, Issue:1 Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; beta 2-Glycoprotein I; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoglobulin G; Immunoglobulin M; Leprostatic Agents; Leprosy; Leprosy, Multibacillary; Logistic Models; Male; Middle Aged; Prednisone; Thalidomide	2019
Thalidomide as a potential adjuvant treatment for paraneoplastic pemphigus: A single-center experience. Dermatologic therapy, 2020, Volume: 33, Issue:6 Topics: Humans; Neoplasm Recurrence, Local; Paraneoplastic Syndromes; Pemphigus; Prednisone; Thalidomide	2020
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic. Dermatologic therapy, 2020, Volume: 33, Issue:6 Topics: Adult; Antibodies, Monoclonal, Humanized; COVID-19; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Methotrexate; Prednisone; Psoriasis; SARS-CoV-2; Thalidomide	2020
Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study. Frontiers in immunology, 2020, Volume: 11 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Behcet Syndrome; Cohort Studies; Colchicine; Drug Combinations; Female; France; Humans; Male; Middle Aged; Prednisone; Thalidomide; Treatment Outcome	2020
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European journal of haematology, 2021, Volume: 107, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Czech Republic; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Registries; Thalidomide; Treatment Outcome	2021
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids. Nature communications, 2021, 12-01, Volume: 12, Issue:1 Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glucocorticoids; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Prednisone; Protein Kinase Inhibitors; Signal Transduction; STAT3 Transcription Factor; Thalidomide; Tumor Necrosis Factor Inhibitors; Up-Regulation	2021
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study. Hematological oncology, 2022, Volume: 40, Issue:4 Topics: Anemia; Danazol; Hemoglobins; Humans; Myeloproliferative Disorders; Nitriles; Pilot Projects; Prednisone; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Thalidomide; Thrombocytopenia; Transaminases; Treatment Outcome	2022
Systemic treatment for severe atopic dermatitis in children: a case series. Boletin medico del Hospital Infantil de Mexico, 2022, Volume: 79, Issue:5 Topics: Azathioprine; Child; Child, Preschool; Cyclosporine; Dermatitis, Atopic; Humans; Methotrexate; Mycophenolic Acid; Prednisone; Thalidomide	2022
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma. Asian journal of surgery, 2023, Volume: 46, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Prednisone; Procarbazine; Rituximab; Thalidomide; Treatment Outcome	2023